This site is intended for Great Britain healthcare professionals only

Visit Pfizer Medical site

Menu

Close

Sign InLog Out
  • EN
Single LinkDropdownLabelLinkLinkLinkLinkLinked DropdownLabelLinkLinkLinkLinkMega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLinked Mega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLinkEN - EnglishSelect a languageLanguagesEN - EnglishFR - Françias

Menu

Close

Sign InLog Out
  • EN
Single LinkDropdownLabelLinkLinkLinkLinkLinked DropdownLabelLinkLinkLinkLinkMega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLinked Mega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLinkEN - EnglishSelect a languageLanguagesEN - EnglishFR - FrançiasSearch

Menu

Close

Sign In or RegisterLog Out
Pfizer MedicinesTherapy AreasExplore ContentEventsVideosMaterialsFeatured ArticlesLet’s ConnectSupplyAlliance HealthcareOff-contract claims

Menu

Close

AboutAboutHow Cibinqo worksIntroducing CibinqoMOA OverviewAtopic DermatitisPatient ProfilesPatient Profiles OverviewPatient Profile 1Patient Profile 2Patient Profile 3Patient Profile 4EfficacyEfficacyClinical EfficacyStudy OverviewJADE COMPAREJADE MONOJADE REGIMENJADE TEENJADE EXTENDJADE DARESafety
Safety
 
Safety
 
Safety GuidanceDosingDosingDosingStarting your patients on CibinqoPractical considerationsSupport & ResourcesSupport & ResourcesHCP ResourcesMedicine Evidence InformationPatient ResourcesVideos
MaterialsContact us

Information on how to access Cibinqo®▼ (abrocitinib) prescribing information and adverse event reporting can be found at the bottom of the page. 
Updated Safety Recommendation - Abrocitinib should only be used if no suitable treatment alternatives are available in patients: 65 years of age and older, patients with history of atherosclerotic cardiovascular disease or other cardiovascular risk factors (such as current or past long-time smokers), patients with malignancy risk factors (e.g. current malignancy or history of malignancy). (Cibinqo Summary of Product Characteristics)

PATIENT PROFILE 4Teenage competitive swimmer suffering with moderate-to-severe atopic dermatitis and regular disease flares and itching​​​​​​​Who is the patient?

Cibinqo is indicated for the treatment of moderate-to-severe AD in adults and adolescents 12 years and older who are candidates for systemic therapy.1

This patient profile is fictional and has been produced for the purposes of medical education. Any actual or potential likeness to real individuals is unintentional.

  • Anglo-Chinese female, 14 years old
  • Disease and treatment history: Diagnosis of AD at age 12; prone to seasonal flares that are particularly itchy. Various treatments tried but lesions continue to worsen; treatments included topical corticosteroids for flare management, TCI (pimecrolimus 1% BID) and phototherapy
  • Clinical assessment: EASI=24; 40% BSA (primarily the torso and legs)
  • Personal impact: A competitive swimmer who trains daily (which may exacerbate her flares), she is very conscious of her lesions and is considering giving up the sport due to appearance-related bullying
  • Preferences: Severely needle-phobic, but her parents have indicated they could manage injections if absolutely necessary
Why consider Cibinqo (abrocitinib)?1. Significantly more patients achieved skin clearance (IGA 0/1) at Week 12 with Cibinqo vs placebo1,2

In 12 weeks, 41.6% of adolescent patients treated with Cibinqo 100 mg achieved IGA 0/1 vs 24.5% with placebo (P<0.05).1–3JADE TEEN (PRIMARY ENDPOINT: IGA 0/1 at Week 12)Proportion of patients achieving IGA 0/1 at Week 12 (in combination with medicated topical therapy)1-3
Scroll left to view table

Patients used non-medicated emollient at least twice a day starting 7 days before initiation of study treatment and medicated topical therapy such as corticosteroids and other medicated topicals per protocol guidance initiated after the baseline visit and until active lesions were under control.3

The recommended starting dose for adolescents (12–17 years old) is 100 mg once daily1

2.Significantly more patients achieved skin clearance (EASI-75)
with Cibinqo vs placebo1,2

In 12 weeks, 68.5% of adolescent patients treated with Cibinqo 100 mg achieved EASI-75 vs 41.5% with placebo (P<0.05).1–3JADE TEEN (PRIMARY ENDPOINT: EASI-75 AT WEEK 12)Proportion of patients achieving EASI-75 (in combination with medicated topical therapy)1-3Example
Scroll left to view table

Patients used non-medicated emollient at least twice a day starting 7 days before initiation of study treatment and medicated topical therapy such as corticosteroids and other medicated topicals per protocol guidance initiated after the baseline visit and until active lesions were under control.3

The recommended starting dose for adolescents (12–17 years old) is 100 mg once daily.1

3. Itch relieved with Cibinqo in adolescents1,2

After 2 weeks, 27.2% of adolescent patients treated with Cibinqo 100 mg achieved PP-NRS4 vs 12.6% with placebo (P=0.0119).1,2JADE TEEN (KEY SECONDARY ENDPOINT: PP-NRS4 at Weeks 2,4 and 12)Proportion of patients achieving PP-NRS4 (in combination with medicated topical therapy)1-3
Scroll left to view table

Patients used non-medicated emollient at least twice a day starting 7 days before initiation of study treatment and medicated topical therapy such as corticosteroids and other medicated topicals per protocol guidance initiated after the baseline visit and until active lesions were under control.3

The recommended starting dose for adolescents (12–17 years old) is 100 mg once daily.1

4. Help your moderate-to-severe atopic dermatitis patients reduce flares* with Cibinqo 100mg (compared with placebo)1,4

Whether continuing on Cibinqo 200 mg or decreasing dose to Cibinqo 100 mg, patients had a significantly higher probability of preventing flares up to Week 52 with Cibinqo vs placebo.1,2JADE REGIMEN (PRIMARY ENDPOINT: FLARE REQUIRING RESCUE MEDICATION DURING MAINTENANCE PERIOD)Cumulative probability of patients experiencing a flare1,4*Protocol-defined flare definition: A loss of at least 50% of the EASI response at Week 12 and an IGA score of 2 or higher. †This study included a 12-week induction period.The recommended starting dose for adolescent patients (12–17 years old) is 100 mg once daily.1
Explore morePatient 1

Unemployed male with moderate-to-severe atopic dermatitis and increasingly uncontrolled itching leading to sleep deprivation, weight gain and low self-esteem.

View profile​​​​​​​LoadingPatient 2

Middle-aged mother with moderate-to-severe atopic dermatitis and uncontrolled, severe eczematous lesions, resulting in selfconsciousness and anxiety.

View profile​​​​​​​​​​​​​​Loading

AD=atopic dermatitis; BID=twice daily; BSA=body surface area; CI=confidence interval; EASI=Eczema Area and Severity Index; HR=hazard ratio; IGA=Investigator’s Global Assessment; LSM=least squares mean; NS=not significant; OD=once daily; OL=open label; PP-NRS=Peak Pruritus Numerical Rating Scale.

Prescribing information:
Cibinqo (abrocitinib) | Prescribing Information (Great Britain)

References:

Cibinqo (abrocitinib) Summary of Product Characteristics.Eichenfield L, et al. JAMA Dermatol 2021;157(10)1165-1173.Eichenfield L, et al. JAMA Dermatol 2021;157(10)1165-1173. Supplementary appendix 3Blauvelt A, et al. JAAD 2022;86(1): 104-112.
PP-CIB-GBR-0696. March 2023

Cibinqo Risk Minimisation Programme (RMP) materials, including a Patient Card and Prescriber Brochure, are available from https://www.medicines.org.uk/emc/product/12874/rmms. Patients treated with Cibinqo should be given the Patient Card.

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search 

for MHRA Yellow Card in Google Play or Apple App Store

 

Adverse events should also be reported to Pfizer Medical Information on 01304 616161

PfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign In or RegisterAccountSign Out

This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc

 

This website is brought to you by Pfizer Limited, a company registered in England 

and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ

 

Copyright © 2023 Pfizer Limited. All rights reserved.

 

VAT registration number GB201048427

PP-UNP-GBR-7284. November 2023
For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-PFE-GBR-3863. November 2021

YesNo
You are now leaving PfizerPro​​​​​
​
​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned or controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site.​​​​​​​​​​​​​​

​​​​​​​PP-PFE-GBR-3858. November 2021​​​​​​​
​​​​​​​
You are now leaving PfizerPro
​​​​​​​
​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site other than the information or other materials relating to ​​​​​Pfizer medicines or 
business which it has provided or reviewed.

PP-PFE-GBR-3859. November 2021
​​​​​​​